Ascendis Pharma AS (NASDAQ:ASND) shares traded down 1.7% during trading on Monday . The company traded as low as $19.28 and last traded at $19.96, with a volume of 68,740 shares traded. The stock had previously closed at $20.30.

A number of research analysts have recently commented on the stock. TheStreet raised shares of Ascendis Pharma AS from a “sell” rating to a “hold” rating in a research report on Tuesday, September 6th. Leerink Swann reissued a “buy” rating on shares of Ascendis Pharma AS in a research report on Friday, September 2nd. Finally, Zacks Investment Research cut shares of Ascendis Pharma AS from a “hold” rating to a “sell” rating in a research report on Tuesday, May 24th.

The stock’s market cap is $502.85 million. The company has a 50-day moving average price of $17.55 and a 200-day moving average price of $15.98.

Ascendis Pharma AS (NASDAQ:ASND) last announced its earnings results on Wednesday, August 31st. The company reported ($0.59) EPS for the quarter, beating the consensus estimate of ($0.69) by $0.10. Equities analysts anticipate that Ascendis Pharma AS will post ($3.17) EPS for the current year.

Ascendis Pharma AS Company Profile

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop a pipeline of long-acting prodrug therapies that address markets with unmet medical needs. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.

5 Day Chart for NASDAQ:ASND

Receive News & Ratings for Ascendis Pharma AS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma AS and related companies with Analyst Ratings Network's FREE daily email newsletter.